.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Deloitte
Citi
Express Scripts
Moodys
Queensland Health
Fish and Richardson
Daiichi Sankyo
McKesson
Federal Trade Commission

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,618,135

« Back to Dashboard

Which drugs does patent 8,618,135 protect, and when does it expire?


Patent 8,618,135 protects JUXTAPID and is included in one NDA.

This patent has twenty-three patent family members in sixteen countries.

Summary for Patent: 8,618,135

Title:Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Abstract: The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.
Inventor(s): Rader; Daniel J. (Philadelphia, PA)
Assignee: The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:13/046,118
Patent Claim Types:
see list of patent claims
Use; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-001Dec 21, 2012RXYesNo► Subscribe► Subscribe► SubscribeA DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-002Dec 21, 2012RXYesNo► Subscribe► Subscribe► SubscribeA DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-003Dec 21, 2012RXYesNo► Subscribe► Subscribe► SubscribeA DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-004Apr 23, 2015RXYesNo► Subscribe► Subscribe► SubscribeA DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-005Apr 23, 2015RXYesNo► Subscribe► Subscribe► SubscribeA DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-006Apr 23, 2015RXYesYes► Subscribe► Subscribe► SubscribeA DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,618,135

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,932,268Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects► Subscribe
9,433,617Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects► Subscribe
9,364,470Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects► Subscribe
9,265,758Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,618,135

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Spain2399721► Subscribe
Denmark1725234► Subscribe
European Patent Office1725234► SubscribeCA 2014 00002Denmark► Subscribe
European Patent Office1725234► SubscribeC300634Netherlands► Subscribe
European Patent Office1725234► SubscribePA2014001Lithuania► Subscribe
European Patent Office1725234► SubscribeC20140001 00107Estonia► Subscribe
European Patent Office1725234► Subscribe14C0003France► Subscribe
European Patent Office1725234► Subscribe1490006-2Sweden► Subscribe
European Patent Office1725234► Subscribe92349Luxembourg► Subscribe
European Patent Office1725234► Subscribe206 5001-2014Slovakia► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Fish and Richardson
Julphar
Baxter
Accenture
Federal Trade Commission
Citi
Mallinckrodt
Medtronic
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot